Loading
IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Can both act as a transcriptional activator or repressor. Plays a negative regulatory role in cells of the immune system.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)).
No product in this corpus aims at IRF8 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA IRF8: RNA tissue enhanced (lymphoid tissue 196 nTPM); blood lineage lineage enriched (dendritic cells 2,405 nTPM); high antibody staining in 4 normal tissues; highest cancer staining glioma (1 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (B-cell chronic lymphocytic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas IRF8 tissue; Open Targets ENSG00000140968 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Weisz et al, J. Biol. Chem, 1992, "Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes". Source.
Sources: HGNC HGNC:5358 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02556 (protein name, function text, keywords and locations (REST API)); CIViC gene IRF8 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000140968 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, leukaemia 0.56 (GraphQL API, CC0))
Transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Can both act as a transcriptional activator or repressor. Plays a negative regulatory role in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes. Required for the development of plasmacytoid dendritic cells (pDCs), which produce most of the type I IFN in response to viral infection. Positively regulates macroautophagy in dendritic cells. Location: Nucleus; Cytoplasm (UniProt). Locus 16q24.1 (HGNC).
RNA: tissue enhanced (lymphoid tissue 196 nTPM), detected in many normal tissues. Blood: lineage enriched (dendritic cells 2,405 nTPM).
Medium: Bone marrow, Lung, Spleen, Testis.
Medium only: liver cancer, stomach cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IRF8" OR ABSTRACT:"IRF8" OR TITLE:"interferon regulatory factor 8" OR ABSTRACT:"interferon regulatory factor 8" OR TITLE:"Interferon regulatory factor 8" OR ABSTRACT:"Interferon regulatory factor 8" OR TITLE:"IRF-8" OR ABSTRACT:"IRF-8" OR TITLE:"ICSBP" OR ABSTRACT:"ICSBP" OR TITLE:"ICSBP1" OR ABSTRACT:"ICSBP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRF8, not a curated reading list.
Shares Leukaemia (all types), CIViC, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.